Our most advanced candidate, danuglipron, has shown good efficacy in a twice-daily formulation, and we believe a once-daily formulation could be highly competitive in the oral GLP-1 space, said Mikael Dolsten, MD., PhD., Chief Scientific Officer & President, Pfizer Research and Development
( A - K ) Gipr fl/fl / Vehicle (n=8), Gipr fl/fl / mGIPR-Ab (n=7), Gipr Syn / / Vehicle (n=14), Gipr Syn / / mGIPR-Ab (n=14)
Extracellular matrix remodeling in chronic liver disease
For detailed information on what BPC-157 is and how it was discovered, that guide provides thorough background
[Medication name] is FDA-approved for [specific indication - Type 2 diabetes/chronic weight management] and is recommended by [relevant medical associations] for patients meeting specific criteria, which I satisfy